Innovative treatment programs against cancer: II. Nuclear factor-κB (NF-κB) as a molecular target

Biochemical Pharmacology

Volumn 57, Issue 1, 1999, Pages 9-17

  Waddick, Kevin G ^a   Uckun, Fatih M ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

Apoptosis; Cancer; Molecular target; Rational drug design; Signal transduction

Indexed keywords

CYTOTOXIC AGENT; GLIOTOXIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; ONCOPROTEIN; PROTEIN A20; PROTEIN BCL 3; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; RAF PROTEIN; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032954699     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00224-X     Document Type: Article

References (72)

1. Mercurio F., Zhu H., Murray B.W., Shevchenko A., Bennett B.L., Li J.W., Young D.B., Barbosa M., Mann M., Manning A., Rao A. IKK-1 and IKK-2 Cytokine-activated IκB kinases essential for NF-κB activation . Science. 278:1997;860-866.
2. Beg A.A., Finco T.S., Nantermet P.V., Baldwin A.S. Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα A mechanism for NF-κB activation . Mol Cell Biol. 13:1993;3301-3310.
3. Thanos D., Maniatis T. NF-κB A lesson in family values . Cell. 80:1995;529-532.
4. Finco T.S., Baldwin A.S. Mechanistic aspects of NF-κB regulation The emerging role of phosphorylation and proteolysis . Immunity. 3:1995;263-272.
5. Baeuerle P.A., Baltimore D. NF-κB Ten years after . Cell. 87:1996;13-20.
6. Baldwin A.S. Jr. The NF-κB and IκB proteins New discoveries and insights . Annu Rev Immunol. 14:1996;649-681.
7. Woronicz J.D., Gao X., Cao Z., Rothe M., Goeddel D.V. IκB kinase-β NF-κB activation and complex formation with IκB kinase-α and NIK . Science. 278:1997;866-869.
8. Whiteside S.T., Ernst M.K., LeBail O., Laurent-Winter C., Rice N., Israel A. N- and C-Terminal sequences control degradation of MAD3/IκB-α in response to inducers of NF-κB activity. Mol Cell Biol. 15:1995;5339-5345.
9. Seger R., Biener Y., Feinstein R., Hanoch T., Gazit A., Zick Y. Differential activation of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a TPA-stimulated protein-tyrosine kinase. J Biol Chem. 270:1995;28325-28330.
10. Schouten G.J., Vertegaal A.C., Whiteside S.T., Israel A., Toebes M., Dorsman J.C., van der Eb A.J., Zantema A. IκB-α is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO J. 16:1997;3133-3144.
11. Fukunaga R., Hunter T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16:1997;1921-1933.
12. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids Inhibition of NF-κB activity through induction of IκB synthesis . Science. 270:1995;286-290.
13. Imbert V., Rupec R.A., Livolsi A., Pahl H.L., Traenckner E.B., Mueller-Dieckmann C., Farahifar D., Rossi B., Auberger P., Baeuerle P.A., Peyron J.F. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α Cell. 86:1996;787-798.
14. fyn tyrosine kinases in human lymphocytes. Blood. 82:1993;1212-1220.
15. Courtois G., Whiteside S.T., Sibley C.H., Israel A. Characterization of a mutant cell line that does not activate NF-κB in response to multiple stimuli. Mol Cell Biol. 17:1997;1441-1449.
16. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., FitzGerald M.J., Rothstein T.L., Sherr D.H., Sonenshein G.E. Inhibition of NF-κB/Rel induces apoptosis of murine B cells. EMBO J. 15:1996;4682-4690.
17. Traenckner E.B., Wilk S., Baeuerle P.A. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J. 13:1994;5433-5441.
18. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA. 94:1997;10057-10062.
19. Yamagishi N., Miyakoshi J., Takebe H. Enhanced radiosensitivity by inhibition of nuclear factor κB activation in human malignant glioma cells. Int J Radiat Biol. 72:1997;157-162.
20. Wang C.-Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis Potentiation by inhibition of NF-κB . Science. 274:1996;784-787.
21. Wu M., Arsura M., Bellas R.E., FitzGerald M.J., Lee H., Schauer S.L., Sherr D.H., Sonenshein G.E. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol. 16:1996;5015-5025.
22. Lee H., Arsura M., Wu M., Duyao M., Buckler A.J., Sonenshein G.E. Role of Rel-related factors in control of c-myc gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med. 181:1995;1169-1177.
23. Liu Z.Q., Kunimatsu M., Yang J.P., Ozaki Y., Sasaki M., Okamoto T. Proteolytic processing of nuclear factor κB by calpain in vitro. FEBS Lett. 385:1996;109-113.
24. Jacque J.M., Fernandez B., Arenzana-Seisdedos F., Thomas D., Baleux F., Virelizier J.L., Bachelerie F. Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes. J Virol. 70:1996;2930-2938.
25. Shatrov V.A., Ratter F., Gruber A., Droge W., Lehmann V. HIV type 1 glycoprotein 120 amplifies tumor necrosis factor-induced NF-κB activation in Jurkat cells. AIDS Res Hum Retroviruses. 12:1996;1209-1216.
26. Carrasco D., Rizzo C.A., Dorfman K., Bravo R. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J. 15:1996;3640-3650.
27. Yoon D.-W., Lee H., Seol W., DeMaria M., Rosenzweig M., Jung J.U. Tap A novel cellular protein that interacts with Tip of herpesvirus saimiri and induces lymphocyte aggregation . Immunity. 6:1997;571-582.
28. Schmitz M.L., Indorf A., Limbourg F.P., Stadtler H., Traenckner E.B., Baeuerle P.A. The dual effect of adenovirus type 5 E1A 13S protein on NF-κB activation is antagonized by E1B 19K. Mol Cell Biol. 16:1996;4052-4063.
29. Claudio E., Segade F., Wrobel K., Ramos S., Bravo R., Lazo P.S. Molecular mechanisms of TNF-α cytotoxicity Activation of NF-κB and nuclear translocation . Exp Cell Res. 224:1996;63-71.
30. Nicola N.A. Cytokines and Their Receptors. 1994;Oxford University Press, New York.
31. Arsura M., Wu M., Sonenshein G.E. TGF β1 inhibits NF-κB/Rel activity inducing apoptosis of B cells Transcriptional activation of IκB-α Immunity. 5:1996;31-40.
32. Suardet L., Li C., Little J.B. Radio-induced modulation of transforming growth factor β1 sensitivity in a p53 wild-type human colorectal-cancer cell line. Int J Cancer. 68:1996;126-131.
33. Raynal S., Nocentini S., Croisy A., Lawrence D.A., Jullien P. Transforming growth factor-β1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer. 72:1997;356-361.
34. Islam K.N., Kayanoki Y., Kaneto H., Suzuki K., Asahi M., Fujii J., Taniguchi N. TGF-β1 triggers oxidative modifications and enhances apoptosis in HIT cells through accumulation of reactive oxygen species by suppression of catalase and glutathione peroxidase. Free Radic Biol Med. 22:1997;1007-1017.
35. Tanaka S., Wands J.R. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor β1-induced apoptosis. Cancer Res. 56:1996;3391-3394.
36. Pahl H.L., Krauss B., Schulze-Osthoff K., Decker T., Traenckner E.B., Vogt M., Myers C., Parks T., Warring P., Muhlbacher A., Czernilofsky A.P., Baeuerle P.A. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB. J Exp Med. 183:1996;1829-1840.
37. Kobayashi M., Mullbacher A., Waring P., Hapel A.J. Gliotoxin treatment selectively spares M-CSF- plus IL-3-responsive multipotent haemopoietic progenitor cells in bone marrow. Eur J Haematol. 46:1991;205-211.
38. Beaver J.P., Waring P. Lack of correlation between early intracellular calcium ion rises and the onset of apoptosis in thymocytes. Immunol Cell Biol. 72:1994;489-499.
39. Piva T.J. Gliotoxin induces apoptosis in mouse L929 fibroblast cells. Biochem Mol Biol Int. 33:1994;411-419.
40. Waring P., Newcombe N., Edel M., Lin Q.H., Jiang H., Sjaarda A., Piva T., Mullbacher A. Cellular uptake and release of the immunomodulating fungal toxin gliotoxin. Toxicon. 32:1994;491-504.
41. 2+ salts. Int J Immunopharmacol. 12:1990;445-457.
42. 2+ release from intact rat liver mitochondria. Biochemistry. 33:1994;13401-13405.
43. Hara M., Han M. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. Proc Natl Acad Sci USA. 92:1995;3333-3337.
44. s6k S6 kinases by growth hormone in 3T3-F442A preadipocytes. Biochem Biophys Res Commun. 193:1993;284-290.
45. rsk in rat pancreatic acini through protein kinase C. Am J Physiol. 272:1997;G401-G407.
46. Petritsch C., Woscholski R., Edelmann H.M., Parker P.J., Ballou L.M. Selective inhibition of p70 S6 kinase activation by phosphatidylinositol 3-kinase inhibitors. Eur J Biochem. 230:1995;431-438.
47. Li S., Janosch P., Tanji M., Rosenfeld G.C., Waymire J.C., Mischak H., Kolch W., Sedivy J.M. Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. EMBO J. 14:1995;685-696.
48. De Valck D., Heyninck K., Van Criekinge W., Vandenabeele P., Fiers W., Beyaert R. A20 inhibits NF-κB activation independently of binding to 14-3-3 proteins. Biochem Biophys Res Commun. 238:1997;590-594.
49. Zhang Q., Didonato J.A., Karin M., McKeithan T.W. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins. Mol Cell Biol. 14:1994;3915-3926.
50. Kerr L.D., Duckett C.S., Wamsley P., Zhang Q., Chiao P., Nabel G., McKeithan T.W., Baeuerle P.A., Verma I.M. The proto-oncogene BCL-3 encodes an IκB protein. Genes Dev. 6:1992;2352-2363.
51. Sun S.C., Maggirwar S.B., Harhaj E. Activation of NF-κB by phosphatase inhibitors involves the phosphorylation of IκB-α at phosphatase 2A-sensitive sites. J Biol Chem. 270:1995;18347-18351.
52. Driscoll J., Frydman J., Goldberg A.L. An ATP-stabilized inhibitor of the proteasome is a component of the 1500-kDa ubiquitin conjugate-degrading complex. Proc Natl Acad Sci USA. 89:1992;4986-4990.
53. Milligan S.A., Owens M.W., Grisham M.B. Inhibition of IκB-α and IκB-β proteolysis by calpain inhibitor I blocks nitric oxide synthesis. Arch Biochem Biophys. 335:1996;388-395.
54. Whiteside S.T., Epinat J.C., Rice N.R., Israel A. IκB-ε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 16:1997;1413-1426.
55. Guo G.G., Gu M., Etlinger J.D. 240-kDa Proteasome inhibitor (CF-2) is identical to δ-aminolevulinic acid dehydratase. J Biol Chem. 269:1994;12399-12402.
56. Bai A., Forman J. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J Immunol. 159:1997;2139-2146.
57. 1 phase. Biochem Biophys Res Commun. 236:1997;555-558.
58. Cerundolo V., Benham A., Brau V., Mukherjee S., Gould K., Macino B., Neefjes J., Townsend A. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol. 27:1997;336-341.
59. Dick L.R., Cruikshank A.A., Destree A.T., Grenier L., McCormack T.A., Melandri F.D., Nunes S.L., Palombella V.J., Parent L.A., Plamondon L., Stein R.L. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem. 272:1997;182-188.
60. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654.
61. WAF1/CIP1 expression. Biochem Biophys Res Commun. 227:1996;564-569.
62. Yang M.-X., Cederbaum A.I. Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. Arch Biochem Biophys. 341:1997;25-33.
63. Kho C.J., Huggins G.S., Endege W.O., Hsieh C.M., Lee M.E., Haber E. Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A. J Biol Chem. 272:1997;3845-3851.
64. Kim T.K., Maniatis T. Regulation of interferon-γ-activated STAT1 by the ubiquitin-proteasome pathway. Science. 273:1996;1717-1719.
65. Yu C.L., Burakof S.J. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J Biol Chem. 272:1997;14017-14020.
66. Bai J.P., Chang L.L. Effects of enzyme inhibitors and insulin concentration on transepithelial transport of insulin in rats. J Pharm Pharmacol. 48:1996;1078-1082.
67. Griscavage J.M., Wilk S., Ignarro L.J. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-κB. Proc Natl Acad Sci USA. 93:1996;3308-3312.
68. Maggirwar S.B., Harhaj E., Sun S.-C. Activation of NF-κB/Rel by Tax involves degradation of IκBα and is blocked by a proteasome inhibitor. Oncogene. 11:1995;993-998.
69. Woo S.K., Baek S.H., Lee J.I., Yoo Y.J., Cho C.M., Kang M.S., Chung C.H. Purification and characterization of a new ubiquitin C-terminal hydrolase (UCH-1) with isopeptidase activity from chick skeletal muscle. J Biochem (Tokyo). 121:1997;684-689.
70. Shaeffer J.R., Cohen R.E. Differential effects of ubiquitin aldehyde on ubiquitin and ATP-dependent protein degradation. Biochemistry. 35:1996;10886-10893.
71. Cuervo A., Hu W., Takamatsu S., Adra C.N., Dice F., Lim B. Proteolysis of NF-κB inhibitors, IκBα and β, by lysosomes. Blood. 90:(Suppl 1):1997;54a.
72. Chen F., Lu Y., Kuhn D.C., Maki M., Shi X., Sun S.C., Demers L.M. Calpain contributes to silica-induced IκB-α degradation and nuclear factor-κB activation. Arch Biochem Biophys. 342:1997;383-388.